A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Genentech
- 16 Jan 2019 Last checked against ClinicalTrials.gov record.
- 30 Aug 2018 Planned End Date changed from 18 Mar 2019 to 29 Mar 2019.
- 30 Aug 2018 Planned primary completion date changed from 18 Mar 2019 to 29 Mar 2019.